Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

NCT01522976 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01522976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01522976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2012
Completion date
March 31, 2027
Enrollment
282 (actual)
Sites
294

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, chronic myelomonocytic leukemia-1, chronic myelomonocytic leukemia-2, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with excess blasts-1, myelodysplastic syndrome/acute myeloid leukemia